Slingshot Insights | Bxlt Overview

BXLT Overview

Upcoming Projects (BXLT)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (BXLT)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (BXLT)

Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission; review expected to be complete in the second half of 2016
Ticker: BXLT
Occurred on: Mar 11, 2017
Shire acquires Baxalta for $45.57 per share ($32B). The deal represents a 13.9% premium to Baxalta's closing price
Tickers: SHPG, BXLT
Occurred on: Jun 03, 2016
Baxalta Commences Phase 1 Clinical Trial of BAX 826, the Company’s Second Extended Half-Life Factor VIII Treatment for Hemophilia A
Ticker: BXLT
Occurred on: Mar 04, 2016
Onconova Therapeutics, Inc. Receives Notice of Termination for Convenience from Baxalta for rigosertib
Tickers: BXLT, ONTX
Occurred on: Mar 03, 2016
Baxalta Submits Marketing Authorization Application to the European Medicines Agency for ADYNOVI for Treatment of Hemophilia A Patients
Ticker: BXLT
Occurred on: Mar 02, 2016
CTI BioPharma Initiates Rolling Submission of U.S. New Drug Application for Pacritinib for the Treatment of Patients with Myelofibrosis, Completion date overdue
Tickers: CTIC, BXLT
Occurred on: Feb 09, 2016
Coherus and Baxalta announce that a Phase 3 clinical trial comparing their biosimilar candidate to Amgen's Enbrel (etanercept), CHS-0214, in patients with rheumatoid arthritis met its primary endpoint of demonstrating equivalence
Tickers: CHRS, BXLT
Occurred on: Jan 11, 2016
Boehringer Ingelheim's Praxbind Approved by FDA for Use As an Emergency Reversing Agent in Patients Taking Pradaxa
Tickers: BOEHRINGER INGELHEIM, PTLA, BXLT, PFE, BMY
Occurred on: Oct 16, 2015

Strategic Initiatives (BXLT)

Don’t see a strategic initiative related to the company you care about? Create your own!